Hence, efforts have focused on identifying therapeutic strategies which use TRAIL – or a different TRA – as the trigger of extrinsic apoptosis in combination with other therapeutic approaches, mostly small molecule inhibitors that target the above-mentioned checkpoints, thereby aiming to sensitize cancer cells to TRAIL-induced apoptosis in order to obtain a maximum therapeutic window with little to no toxicity. The gene discussed is TNFSF10; the disease is cancer.